Novartis/Sandoz make history with 1st US biosimilar Zarxio
This article was originally published in Scrip
Executive Summary
Novartis and its Sandoz unit made history on 6 March, gaining the first approval of a biosimilar in the US – Zarxio (filgrastim-sndz).
You may also be interested in...
Pfizer Launches Nivestym At An Aggressive Discount To Other Filgrastim Products
Pfizer is launching its second US biosimilar, a version of filgrastim, at an aggressive 30.3% discount to Amgen's branded Neupogen and at a discount to competing biosimilars.
Pfizer Launches Nivestym At An Aggressive Discount To Other Filgrastim Products
Pfizer is launching its second US biosimilar, a version of filgrastim, at an aggressive 30.3% discount to Amgen's branded Neupogen and at a discount to competing biosimilars.
Pfizer/Celltrion Prep For October Inflectra Launch
With Celltrion shipping the first batch of its biosimilar Inflectra (infliximab-dyyb) and a stipulation agreement with Johnson & Johnson, Pfizer is set to launch the product on Oct. 3 – six months after it was approved in the US.